Differential effects of modafinil on performance of low-performing and high-performing individuals during total sleep deprivation
| Autor: | Henry G. Stephenson, Christina L. Kunkle, J. Lynn Caldwell, Valarie M. Schroeder |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Clinical Biochemistry Modafinil Audiology Toxicology Placebo Biochemistry Total sleep deprivation Placebos Young Adult 03 medical and health sciences Behavioral Neuroscience 0302 clinical medicine Double-Blind Method mental disorders Reaction Time Humans Medicine Biological Psychiatry Pharmacology business.industry Drug condition Cognition Wakefulness-Promoting Agents Differential effects 030227 psychiatry Sleep deprivation Sleep Deprivation Wakefulness medicine.symptom business Psychomotor Performance 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Pharmacology Biochemistry and Behavior. 196:172968 |
| ISSN: | 0091-3057 |
| DOI: | 10.1016/j.pbb.2020.172968 |
| Popis: | Background Individual responses to the effects of inadequate sleep have been well documented; some people are more vulnerable to the effects of sleep loss than others. Fatigue-vulnerable individuals generally require access to effective fatigue countermeasures; however, the question arises as to whether these fatigue-vulnerable individuals receive the same benefits shown in group efficacy data. The present study administered modafinil to individuals to determine its differential effects on performance of best and worst performers during sleep deprivation. Methods A sample of 22 men, age 21–40 yrs., was tested on 2 separate occasions during which they were kept awake for 36 h. During one period they received 200 mg modafinil; during the other they received placebo. Participants were tested on a variety of tasks while rested and at 5-hr intervals across the continuous wakefulness period. Performance for each cognitive task and subjective measure of fatigue from the placebo period was used to group individuals into high (HP) or low performance (LP) groups to indicate fatigue vulnerability for each task. Results Results indicated that on the MTS task, the HP group performed the same throughout the testing period, regardless of whether they received modafinil or not. However, the LP group significantly improved after receiving modafinil compared to placebo. Performance on the PVT showed the HP group had a small decrease in the number of lapses after receiving modafinil compared to placebo, whereas the LP group had a large decrease in lapses after receiving modafinil compared to placebo. Performance on the RDM showed no difference between groups, regardless of drug condition. Groups did not differ after receiving modafinil on subjective fatigue measured by the POMS. Conclusions Depending on the task, HP individuals did not benefit substantially when administered modafinil compared to placebo. However, the LP individuals improved after receiving modafinil compared to placebo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect